Can-Fite BioPharma (CANF)
XASE:CANF
Want to see CANF full AI Analyst Report?
CANF Stock Chart & Stats
$4.04
-$0.06(-3.61%)
At close: 4:00 PM EST
$4.04
-$0.06(-3.61%)
Day’s Range― - ―
52-Week Range$2.83 - $23.40
Previous CloseN/A
Volume35.97K
Average Volume (3M)258.05K
Market Cap
$7.18M
Enterprise Value$8.58B
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$90.00K
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 27, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.07
P/FCF Ratio-0.37
Enterprise Value/Market Cap1.19K
Enterprise Value/Revenue15.32K
Enterprise Value/Gross Profit15.32K
Enterprise Value/Ebitda-963.28
Forecast
1Y Price Target
$6.00Price Target Upside48.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low debt relative to equity materially reduces near-term solvency risk and gives management flexibility to prioritize R&D rather than servicing interest. Over a 2–6 month horizon this conservatism lowers bankruptcy risk and preserves optionality for strategic partnerships or staged financings.
Meaningful Clinical Progress For NamodenosonRobust Phase 2a safety and preliminary activity in heavily pretreated pancreatic cancer strengthens the drug’s clinical profile and orphan positioning. Durable disease stabilization and tolerability support continued development, potential regulatory incentives, and longer-term partnering or out‑license opportunities.
Veterinary Partnership Creates Non-dilutive Revenue PathwayA fully partner-funded Phase 2 in canine osteoarthritis shifts development cost and regulatory risk off Can‑Fite, offering a realistic near‑to‑mid-term commercialization route. A potential license stream (up to $325M) diversifies revenue sources and de‑risks reliance on human clinical outcomes for long-term sustainability.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow increases dependence on external capital and shortens effective runway without material near-term commercialization. Over 2–6 months this structural cash burn raises the probability of further financing rounds that can be dilutive or expensive.
Declining Revenue And Ongoing Operating LossesSmall and falling revenues alongside persistent operating losses indicate the company is not yet generating commercial cash flow. This structural lack of product sales constrains organic funding capacity, prolongs reliance on external capital, and weakens the financial foundation for scaling programs.
Reliance On Dilutive Capital ActionsMoves to increase authorized shares and grant executive options, combined with recent repriced warrant exercises, reflect structural funding dependence. These governance and capital actions raise the risk of dilution, which can impair shareholder economics and complicate future fundraising or partnering negotiations.
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $2.83 and its highest was $23.40 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $7.18M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Aug 27, 2026 which is in 93 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Mar 26, 2026. The company reported -$5.97 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$5.83.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.51.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 2,142,546 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$5.97 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 1.858%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
CANF Stock 12 Month Forecast
Average Price Target
$6.00
▲(48.51% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.99% Other Institutional Investors
98.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---